Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Treasury Shares (2022 - 2025)

Historic Treasury Shares for Day One Biopharmaceuticals (DAWN) over the last 4 years, with Q3 2025 value amounting to $2.8 million.

  • Day One Biopharmaceuticals' Treasury Shares rose 4616.86% to $2.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.8 million, marking a year-over-year increase of 4616.86%. This contributed to the annual value of $1.8 million for FY2024, which is 8689.1% up from last year.
  • Latest data reveals that Day One Biopharmaceuticals reported Treasury Shares of $2.8 million as of Q3 2025, which was up 4616.86% from $3.0 million recorded in Q2 2025.
  • In the past 5 years, Day One Biopharmaceuticals' Treasury Shares ranged from a high of $3.0 million in Q2 2025 and a low of $392757.0 during Q1 2022
  • Over the past 4 years, Day One Biopharmaceuticals' median Treasury Shares value was $953913.0 (recorded in 2023), while the average stood at $1.5 million.
  • As far as peak fluctuations go, Day One Biopharmaceuticals' Treasury Shares skyrocketed by 14463.08% in 2024, and later surged by 2730.94% in 2025.
  • Over the past 4 years, Day One Biopharmaceuticals' Treasury Shares (Quarter) stood at $485351.0 in 2022, then skyrocketed by 95.6% to $949370.0 in 2023, then soared by 86.89% to $1.8 million in 2024, then surged by 55.47% to $2.8 million in 2025.
  • Its last three reported values are $2.8 million in Q3 2025, $3.0 million for Q2 2025, and $2.9 million during Q1 2025.